Stoke Therapeutics schedules webcast, call on Q2 business and financial updatePUBT·Jul 27 at 03:01 PMSTOK+1.90%
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statementPUBT·Jul 17 at 03:33 PMSTOK+1.90%
Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?Simplywall·Jul 10 at 08:17 AMSTOK+1.90%
How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet SyndromeSimplywall·Jul 7 at 07:05 PMSTOK+1.90%
Stoke Therapeutics CMO Barry Ticho disposes of common shares worth $235,889.32PUBT·Jul 6 at 03:11 PMSTOK+1.90%
Stoke Therapeutics completes enrollment in Phase 3 EMPEROR trial of Dravet drug zorevunersenPUBT·Jun 30 at 07:02 AMSTOK+1.90%
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?Simplywall·Jun 28 at 11:00 PMSTOK+1.90%
Stoke Therapeutics General Counsel Jonathan Allan sells $43,638.15 in common sharesPUBT·Jun 18 at 03:19 PMSTOK+1.90%
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% - Should You Buy?Market Beat·Jun 12 at 11:43 PMSTOK+1.90%GS-A+0.16%
